Mirum’s Volixibat Delivers Major Win in VISTAS Study – First Potential Treatment for Severe Itching in PSC
Mirum’s drug volixibat reduced severe itching in PSC patients in a Phase 2 trial; next step is FDA filing in 2026.
Mirum’s drug volixibat reduced severe itching in PSC patients in a Phase 2 trial; next step is FDA filing in 2026.
Garda raised bid to $21.80/share cash to buy Assertio, boosting stock ~17%. Deal gives shareholders higher, certain payout.
FDA may fast-track Clene’s ALS drug CNM-Au8 after strong results, offering hope for longer life and slower disease progression.
Celcuity’s drug showed strong results in breast cancer, boosting survival and raising hopes it could become a new standard treatment.
FDA approved Pfizer/Arvinas Veppanu pill for advanced breast cancer with ESR1 mutation, helping hormone-resistant cases.
ARCHIMED will buy Esperion and take it private for $3.16/share (+58% premium) plus up to $100M extra payouts if targets are met.